Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Effect of elinzanetant on sleep disturbance and aspects of quality of life in women with breast cancer experiencing vasomotor symptoms: OASIS-4 subgroup analysis by type of endocrine therapy.

Claudio Soares, Kaisa Laapas, Christian Seitz et al. Jun 01, 2026 pp. 512-512 10.1200/jco.2026.44.16_suppl.512

512 Background: In the Phase III OASIS-4 trial, elinzanetant (EZN), a dual neurokinin (NK)-targeted therapy (NK-1 and NK-3...

Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial.

R. Andrew Harkins, Will Harris, Michael Green et al. Jun 01, 2026 pp. 7017-7017 10.1200/jco.2026.44.16_suppl.7017

7017 Background: Single cell multiomics helped identify three tumor microenvironment archetypes: FMAC, high tumor-associat...

A phase 2 study of androgen deprivation therapy and the androgen receptor ligand–directed degrader (BMS-986365) prior to radical prostatectomy in patients with high-risk localized prostate cancer.

Kristine Peregrino Lacuna, Glenn Heller, Brett Stewart Carver et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5152

TPS5152 Background: Although radical prostatectomy (RP) is a curative approach for patients (pts) with high-risk localized...

Clinical impact of succinate-dehydrogenase B protein expression in clear cell renal cell carcinoma.

Alvaro Pinto, Eugenia García-Fernández, María Pilar González-Peramato et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16511

e16511 Background: Succinate-deficiency renal tumors are considered a new entity since WHO 2016 classification. These tumo...

A machine learning (ML)–based six-gene signature for risk stratification and therapeutic target identification in multiple myeloma.

Sriram Subramanian, Salman Aslam, Shahzad Raza Jun 01, 2026 pp. 7558-7558 10.1200/jco.2026.44.16_suppl.7558

7558 Background: Multiple myeloma(MM) accounts for 10-15% of hematologic malignancies with significant heterogeneity. Curr...

Accelerated failure time as an alternative to Cox proportional hazards for parathyroid carcinoma in the Surveillance, Epidemiology, and End Results database.

Ayla T. Nguyen, Shekhar Gugnani, An-Lin Cheng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18139

e18139 Background: Cox proportional hazards regression is a common model for multivariate survival analysis. This model re...

Evidence implicating human papillomavirus in bladder carcinogenesis: A case-control study.

Xueying Zhang Jun 01, 2026 pp. 4594-4594 10.1200/jco.2026.44.16_suppl.4594

4594 Background: The etiology of high-risk oncogenic human papillomavirus (HPV) subtypes with signature cytomorphological...

A multicenter, prospective real-world study of irinotecan liposome (II)–based combination regimens in patients with pancreatic ductal adenocarcinoma.

Taiping Zhang, Liwei Wang, Zhe Cao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16399

e16399 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited therapeutic options...

Choosing Wisely Pakistan: A call for value-based oncology practice in resource-limited settings.

Sadia Sadiq, Rab Nawaz Maken, Fareeha Sheikh Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13532

e13532 Background: The Choosing Wisely initiative promotes evidence-based oncology care by reducing low-value intervention...

Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers.

Dr Vikas Leelavati Balasaheb Jadhav, Rahul Arkar, Reshma Puranik et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16191

e16191 Background: Tumor thrombus (TT) is often an incidental, leading direct extension of tumor cells into a blood vein....

Characteristics of patients managed with active surveillance versus treatment for prostate cancer within a large nationwide health system.

John R. Bihn, Grace Lee, John Culnan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17129

e17129 Background: Active surveillance (AS) is broadly endorsed as preferred management for low-grade prostate cancer and...

Potential alternative dosing strategies for FDA-approved oncology biologics based on reanalysis of exposure-response data.

Mohamed Ali, Mark J. Ratain Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15135

e15135 Background: Many modern oncology biologics were developed using historical maximum tolerated dose paradigms that ar...

Clinical characteristics, treatment patterns, and outcomes of common solid tumors in Arab American patients.

Shadi Chamseddine, Yingnan Zhang, Yang Shi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23407

e23407 Background: Arab Americans are frequently misclassified as White in U.S. cancer registries, limiting the study of c...

circRNA signatures associated with BRCA mutation status in ovarian cancer and a RASSF8-derived candidate biomarker.

Ciara S. McNevin, Josh Flynn, Martin P. Barr et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17548

e17548 Background: Clinically actionable variants (CAVs) in BRCA1 and...

Improving clinical trial enrollment rates among patients with operable invasive breast cancers: An ASCO Quality Training Program initiative.

Mike Zhou Yang, Jenny Wei, Quyen Chau et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23305

e23305 Background: Clinical trial participation is essential for advancing cancer care and recommended in National Compreh...

Efficacy and safety of SPH4336 plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer with brain metastases: A multicenter, single-arm, phase II study.

Kuikui Jiang, Shusen Wang, Qingyuan Zhang et al. Jun 01, 2026 pp. 1076-1076 10.1200/jco.2026.44.16_suppl.1076

1076 Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors plus endocrine therapy are standard first-line treatment...

Knowledge-distilled EfficientNets for peripheral blood smear classification.

Gowrishankar Palaniswamy, Sravani Bhavanam, Elangovan Krishnan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14083

e14083 Background: Leukemias represent the most common malignancies in children and remain a major source of cancer-relate...

Use of knowledge-distilled EfficientNet to enable rapid, scalable glioma diagnosis.

Gowrishankar Palaniswamy, Elangovan Krishnan, Jansi Rani Sethuraj et al. Jun 01, 2026 pp. 2040-2040 10.1200/jco.2026.44.16_suppl.2040

2040 Background: Accurate preoperative classification of gliomas on MRI according to WHO 2021 integrated diagnosis is esse...

Understanding the role of large language models in cancer mortality prediction: A real-world study.

Xueqing Peng, Maureen Canavan, Huan He et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23177

e23177 Background: Although mortality risk prediction is essential in oncology, risk determinants vary widely across cance...

Trends and disparities in prostate cancer mortality among men with hypertension in the United States: A CDC WONDER analysis (1999–2020).

Suleman Saeed, Hamid Bin Tariq, Faisal Ahmad et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17064

e17064 Background: Prostate cancer is a major cause of cancer-related mortality among older men in the United States. Hype...

Impact of systemic delays in targeted therapy (TT) access for advanced NSCLC (aNCSLC) with actionable genomic alterations (AGA+) in Alberta, Canada.

Vishal Navani, Amanda Williams Gibson, Michelle Liane Dean et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23028

e23028 Background: Approval and funding timelines for precision oncology drugs in Canada lag those of other OECD nations....

A randomized phase Ib/II study of enzalutamide (Enza) with and without ribociclib (Rib) in patients with metastatic castrate-resistant prostate cancer (mCRPC) that retains RB expression: RiboX study.

Kevin Kayvan Zarrabi, Susan F. Slovin, William J. Tester et al. Jun 01, 2026 pp. 5057-5057 10.1200/jco.2026.44.16_suppl.5057

5057 Background: RB function is often attenuated in tumors through hyperphosphorylation; thus, RB activity can be “re-awak...

Impact of transplant on <i>TP53</i> <sup>MT</sup> configurational dynamics in myeloid neoplasms.

Dakshin Sitaram Padmanabhan, Jeff Justin Aguilar, Vikram Dhillon et al. Jun 01, 2026 pp. 6537-6537 10.1200/jco.2026.44.16_suppl.6537

6537 Background: Multihit TP53 clonal configurations in myeloid neoplasms (MN) con...

Efficacy and safety of neoadjuvant ICI-based regimens in resectable gastric and GEJ cancer: Updated systematic review and meta-analysis.

Sana Arif Khan, Mohammad Dawar Zahid, Mazhar Ali et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16124

e16124 Background: Gastric and gastroesophageal junction (GEJ) cancers remain highly lethal, and durable cure relies on cu...

Impact of chemotherapy on gonadal function in pubertal children with Hodgkin lymphoma.

Elena M. Frantsiyants, Valeria Bandovkina, Yuliya Yu. Kozel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22001

e22001 Background: Hodgkin lymphoma (HL) in pubertal children carries a high risk of reproductive dysfunction, both due to...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page